Free tool
FAERS Monitor: Anthim
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125509 or its brand name (Anthim, Obiltoxaximab). Reports on generic versions are filed under their own applications.
Reports
2
Serious
2
100% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- congenital diaphragmatic hernia2
- maternal drugs affecting foetus2
- maternal exposure during pregnancy2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| congenital diaphragmatic hernia | 2 | 54123.8 | 49003.9 | 60,576 |
| maternal drugs affecting foetus | 2 | 2744.3 | 2683.6 | 3,085 |
| maternal exposure during pregnancy | 2 | 236.0 | 234.5 | 264 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.